COURAGE与ISCHEMIA长期随访:初始PCI对稳定型冠心病患者25年内无生存获益
Upfront PCI Still Not Beneficial for Stable CAD as Far Out as 25 Years
COURAGE和ISCHEMIA两项随机对照试验的长期随访结果显示,对稳定型冠状动脉疾病患者而言,初始经皮冠状动脉介入治疗(PCI)联合最佳药物治疗与仅采用保守管理策略相比,在长达25年(COURAGE)和11年(ISCHEMIA)的随访期间均未显示出降低死亡或心肌梗死风险的优势。
COURAGE与ISCHEMIA两项研究的25年和11年随访均未显示初始PCI对稳定型冠心病患者带来生存获益,为长期治疗策略选择提供重要证据。
— No diverging event curves seen in COURAGE and ISCHEMIA long-term outcomes
by Nicole Lou, Senior Staff Writer, MedPage Today
November 11, 2026 • 5 min read
A longer horizon did not give patients with stable coronary artery disease (CAD) any improved hard outcomes when getting an invasive strategy over conservative management, according to extended results from the COURAGE and ISCHEMIA randomized trials.
There were still no diverging event curves to be found up to 25 years into COURAGE nor 11 years into ISCHEMIA, investigators reported at a session dedicated to these follow-up reports at the American Heart Association (AHA) annual meeting held in Chicago.
COURAGE had shown in 2007 that an initial management strategy of adding percutaneous coronary intervention (PCI) to optimal medical therapy (OMT) did not reduce the risk of death or myocardial infarction (MI), at a median 4.6 years of follow-up, in patients with stable CAD. A newer trial, more reflective of modern care, came to the same conclusion: 2019's ISCHEMIA failed to show any 4-year benefit from adding early stenting or bypass surgery to optimal medication in patients with stable, moderate-to-severe ischemic heart disease.
Between-group results remained superimposed in the latest data.
The estimated 25-year cumulative incidence of combined death or MI in COURAGE was 93.3% with added PCI and a similar 91.0% with OMT alone (HR 1.01, 95% CI 0.88-1.15), in a report simultaneously published in JAMA.
In ISCHEMIA, all-cause 11-year mortality was also not significantly different between invasive and conservative management groups (25.8% vs 26.9%, adjusted HR 0.97, 95% CI 0.86-1.09) in a report also released in JAMA.
Similarly, 9 years into ISCHEMIA's parallel trial in patients with concomitant chronic kidney disease (CKD), separately published in Circulation, there was no difference in cumulative all-cause mortality or cardiovascular mortality.
It thus remains debatable what the value is of coronary artery bypass grafting or PCI in chronic coronary disease. Of note, PCI did result in angina relief for people with ischemia refraining from antianginal therapy in the sham-controlled ORBITA-2 trial.
"There are several important lessons that will continue to help guide treatment decisions. A conservative strategy is a safe initial approach in most cases of chronic stable coronary artery disease. A conservative strategy has a slightly higher risk for spontaneous MI that should be considered and balanced against initial procedural risks," according to Donald Cutlip, MD, and Robert Yeh, MD, MSc, both of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, in a JAMA editorial.
"As with all trials, the results are an average outcome based on randomized treatment assignments and apply in this case to the initial strategy with ongoing guideline-directed medical therapy and careful monitoring. For individual patients, the question is whether we can do better by personalized shared decision-making; avoiding risk in those unlikely to benefit while pursuing an early invasive strategy in those with increased likelihood of benefit. This is the real long-term goal," Cutlip and Yeh stressed.
COURAGE
The COURAGE investigators reached a median follow-up of 15 years in their post hoc 25-year report.
Individual components of the primary endpoint were consistently neutral between upfront PCI and OMT:
- Death: 83.9% vs 82.2% (HR 0.98, 95% CI 0.85-1.13)
- MI: 54.6% vs 54.0% (HR 1.01, 95% CI 0.85-1.20)
- Revascularization: 50.4% vs 53.5% (HR 0.87, 95% CI 0.73-1.03)
"Deferred revascularization is inherent in the OMT strategy, so this estimate reflects the strategies as practiced and not necessarily the effect of PCI on outcomes. Nevertheless, it is notable that nearly half of patients randomized to receive OMT alone never required revascularization," wrote study authors Neel Butala, MD, of Rocky Mountain Regional VA Medical Center in Aurora, Colorado, and colleagues.
"The high rate of repeat revascularization among patients randomized to receive PCI likely reflects both the use of predominantly bare metal stents and progression of atherosclerosis in nonstented segments," they added.
Included in this analysis were 959 of the original COURAGE participants enrolled at Veterans Affairs hospitals. Mean age at baseline was 62.7 years and fewer than 2% were women. About 40% had diabetes, and mean left ventricular ejection fraction (LVEF) was just over 59%.
ISCHEMIA, ISCHEMIA-CKD
Median follow-up reached 9 years in ISCHEMIA-EXTEND, the extension study of ISCHEMIA, and 8 years in ISCHEMIA-CKD.
Both were strategy trials that randomized people to upfront coronary angiography (and revascularization when feasible, via PCI or coronary artery bypass graft surgery) and guideline-directed medical therapy or medical therapy alone (invasive management later allowed for failure of medical therapy).
In the main trial, estimated cardiovascular mortality at 11 years was 15.8% and 17.1% (adjusted HR 0.88, 95% CI 0.75-1.02), respectively, and noncardiovascular mortality 9.1% and 8.1% (adjusted HR 1.18, 95% CI 0.96-1.45).
"These results support shared decision-making between patients and their clinicians, clarifying that while a routine invasive strategy improves quality of life for symptomatic patients through at least 4 years over an initial conservative strategy, there is no survival advantage over approximately a decade," reported Judith Hochman, MD, of NYU Grossman School of Medicine/NYU Langone Health in New York City, and colleagues.
Similarly, the ISCHEMIA-CKD trial showed that in patients with at least moderate ischemia and advanced CKD, cumulative all-cause mortality (57.4% vs 56.8%, adjusted HR 1.05, 95% CI 0.87-1.28) and cardiovascular mortality (40.3% vs 38.4%, adjusted HR 1.06, 95% CI 0.84-1.34) were still unimproved with the upfront invasive strategy, according to Sripal Bangalore, MD, MHA, also of NYU Grossman School of Medicine.
All 5,179 participants randomized in the ISCHEMIA trial were included in ISCHEMIA-EXTEND. At baseline, median age was 64 years, 23% of participants were women, 42% had diabetes, and median LVEF was 60%.
ISCHEMIA-CKD had 777 people randomized. Median age at baseline was 63 years, 31% were women, 57% had diabetes, 53% were on dialysis, and median LVEF was 59%.
Cutlip and Yeh cautioned against extrapolation of the numerical trend toward excess late noncardiovascular mortality in ISCHEMIA.
"The findings must also be interpreted in the context of the study's design as a strategy trial that included subsequent invasive angiography in 26% of patients assigned to the conservative strategy during the early phase," they noted. "Given that any differences in outcomes between the two randomized treatment arms would be mediated by the different rates and timing of revascularization in each group, the absence of this information makes interpretation of the study findings, and in particular the effect sizes, difficult."
来源:MedPage Today · medpagetoday.com